IL-2
IL-2 is a biological therapy with 83 clinical trials. Currently 9 active trials ongoing. Historical success rate of 71.4%.
Success Metrics
Based on 40 completed trials
Phase Distribution
Phase Distribution
43
Early Stage
33
Mid Stage
2
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
65.6%
40 of 61 finished
34.4%
21 ended early
9
trials recruiting
83
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML
TREg Activation in the Treatment of the PELADE (Alopecia Areata)
FT819 in Subjects With B-cell Malignancies
Natural Killer-cell Therapy for Acute Myeloid Leukemia
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
Clinical Trials (83)
Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML
TREg Activation in the Treatment of the PELADE (Alopecia Areata)
FT819 in Subjects With B-cell Malignancies
Natural Killer-cell Therapy for Acute Myeloid Leukemia
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade
HPV16 E6 TCR T Cells for Cervical Carcinoma
A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases
Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL
A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies
MIROCALS: Modifying Immune Response and OutComes in ALS
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors
A Clinical Study of the Safety and Activity of the Investigational Cell Therapy NEO-PTC-01 in Patients With Advanced Melanoma
Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors
Adoptive Transfer of iNKT Cells for Treating Patients With Relapsed/Advanced HCC
Vaccination with Autologous Dendritic Cells Loaded with Autologous Tumour Homogenate After Curative Resection for Stage IV Colorectal Cancer.
Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies
TIL Therapy for Patients With Advanced Solid Tumors
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 83